Wei Zhewen, Zhao Jianjun, Bi Xinyu, Zhang Yefan, Zhou Jianguo, Li Zhiyu, Huang Zhen, Zhao Hong, Cai Jianqiang
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hepatobiliary Surg Nutr. 2022 Oct;11(5):709-717. doi: 10.21037/hbsn-20-854.
The prognosis of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is extremely poor. The clinical outcome of preoperative radiotherapy (RT) is still controversial. This study aimed to compare the clinical outcomes of combined neoadjuvant RT and hepatectomy with hepatectomy alone for HCC with PVTT.
Comprehensive database searches were performed in PubMed, the Cochrane Library, EMBASE, and the Web of Science to retrieve studies published from the database creation to July 1, 2020. Only comparative studies that measured survival between neoadjuvant RT followed by hepatectomy and hepatectomy alone were included. The characteristics of the included studies and patients were extracted, and the included data are presented as relative ratio (RR) estimates with 95% confidence intervals (CIs) for all outcomes. The RRs of each study were pooled using a fixed or random effects model with Review Manager (the Cochrane Collaboration, Oxford, UK) version 5.3. The response rate to RT and the overall survival (OS) rate in neoadjuvant RT followed by hepatectomy and hepatectomy alone were measured.
One randomized and two non-randomized controlled trials with 302 patients were included. Most patients were classified as Child-Pugh A, and Type II and III PVTT were the most common types. After RT, 29 (22.8%) patients were evaluated as partial response (PR) and had a positive RT response, but nine (7.1%) had progressive disease (PD). Neoadjuvant RT followed by hepatectomy was received by 127 (42.1%) patients after excluding 15 (5.0%) patients with severe complications or PD after RT, and 160 (53.0%) patients received hepatectomy alone. In the randomized controlled trial (RCT), the 1-year OS rate in the neoadjuvant RT group and the surgery alone group was 75.2% and 43.1%, respectively (P<0.001). In the two non-randomized studies, a meta-analysis with a fixed effects model showed a longer OS in patients undergoing neoadjuvant RT followed by hepatectomy compared with hepatectomy alone at 1-year follow-up (RR =2.02; 95% CI: 1.45-2.80; P<0.0001).
This systematic review showed that neoadjuvant RT followed by hepatectomy in patients with resectable HCC and PVTT was associated with a longer OS than patients who received hepatectomy alone.
伴有门静脉癌栓(PVTT)的肝细胞癌(HCC)预后极差。术前放疗(RT)的临床疗效仍存在争议。本研究旨在比较新辅助放疗联合肝切除术与单纯肝切除术治疗伴有PVTT的HCC的临床疗效。
在PubMed、Cochrane图书馆、EMBASE和科学网进行全面的数据库检索,以检索从数据库创建至2020年7月1日发表的研究。仅纳入测量新辅助放疗后肝切除术与单纯肝切除术之间生存率的比较研究。提取纳入研究和患者的特征,并将纳入数据表示为所有结局的相对比率(RR)估计值及95%置信区间(CI)。使用Review Manager(英国牛津Cochrane协作网)5.3版的固定效应或随机效应模型汇总每项研究的RR值。测量新辅助放疗后肝切除术和单纯肝切除术的放疗缓解率和总生存(OS)率。
纳入1项随机对照试验和2项非随机对照试验,共302例患者。大多数患者为Child-Pugh A级,II型和III型PVTT最为常见。放疗后,29例(22.8%)患者评估为部分缓解(PR),放疗反应为阳性,但9例(7.1%)出现疾病进展(PD)。排除放疗后出现严重并发症或PD的15例(5.0%)患者后,127例(42.1%)患者接受新辅助放疗后肝切除术,160例(53.0%)患者接受单纯肝切除术。在随机对照试验(RCT)中,新辅助放疗组和单纯手术组的1年OS率分别为75.2%和43.1%(P<0.001)。在两项非随机研究中,固定效应模型的荟萃分析显示,新辅助放疗后肝切除术患者在1年随访时的OS较单纯肝切除术患者更长(RR =2.02;95%CI:1.45 - 2.80;P<0.0001)。
本系统评价表明,可切除的HCC合并PVTT患者新辅助放疗后肝切除术较单纯肝切除术患者的OS更长。